Moshe Arkin 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-02 2:23 pm Sale |
2023-01-26 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,371,074 4.980% |
-441,241 (-24.35%) |
Filing |
| 2022-04-12 06:18 am Unchanged |
2022-04-11 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,812,315 7.550% |
0 (Unchanged) |
Filing |
| 2022-04-11 4:57 pm Sale |
2022-04-11 | 13G | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 1,812,315 7.550% |
-223,825 (-10.99%) |
Filing |
| 2020-12-17 06:48 am Unchanged |
2020-12-17 | 13D | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 2,036,140 8.790% |
0 (Unchanged) |
Filing |
| 2020-11-25 06:31 am Unchanged |
2020-11-17 | 13D | Keros Therapeutics, Inc. KROS |
Moshe Arkin | 2,036,140 8.790% |
0 (Unchanged) |
Filing |